This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Garden, A. S. Articles by Peters, L. J. Search for Related Content PubMed PubMed Citation Articles by Garden, A. S. Articles by Peters, L. J. Social Bookmarking                            What's this?

Phase I/II Trial of Radiation With Chemotherapy "Boost" for Advanced Squamous Cell Carcinomas of the Head and Neck: Toxicities and Responses

From the Departments of Radiation Oncology, Thoracic Head and Neck Medical Oncology, and Head and Neck Surgery, The University of Texas M.D. Anderson Cancer Center, Houston, TX.

Address reprint requests to Adam S. Garden, MD, Department of Radiation Oncology, Box 97, U. T. M.D. Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030; email agarden{at}notes.mdacc.tmc.edu

PURPOSE: Extrapolating from our experience delivering a "boost" field of radiation concurrently with fields treating both gross and subclinical disease at the end of a course of radiation therapy, we developed a regimen to deliver concurrent chemotherapy during the last 2 weeks of a conventionally fractionated course of radiation.

PATIENTS AND METHODS: Patients had stage III or IV biopsy-proven squamous cell carcinoma originating from a head and neck mucosal site. The regimen was 70 Gy delivered over 7 weeks with concurrent fluorouracil (5-FU) and cisplatin given daily with each radiation dose during the last 2 weeks. A phase I study was performed to determine the maximum-tolerated dose (MTD) before a phase II study was conducted.

RESULTS: The MTD was 400 mg/m² per day for 5-FU and 10 mg/m² per day for cisplatin. Mucositis persisting more than 6 weeks after therapy was the dose-limiting toxicity. A total of 60 patients were treated on the two phases of the study. Eighteen patients (35%) treated at the MTD developed prolonged mucositis. There were two cases of neutropenic sepsis, including one fatality. The actuarial 2-year rates for overall survival, freedom from relapse, and local control were 62%, 59%, and 80%, respectively.

CONCLUSION: Preliminary locoregional control rates seem to be higher than those reported for treatment with radiation alone. Toxicity was also greater than that seen with radiation alone, but the regimen was designed to deliver an intense treatment schedule, which could be completed without significant interruptions, and to obtain high control rates above the clavicles. These end points were achieved.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				M. Yamaguchi, K. Tobinai, M. Oguchi, N. Ishizuka, Y. Kobayashi, Y. Isobe, K. Ishizawa, N. Maseki, K. Itoh, N. Usui, et al. Phase I/II Study of Concurrent Chemoradiotherapy for Localized Nasal Natural Killer/T-Cell Lymphoma: Japan Clinical Oncology Group Study JCOG0211 J. Clin. Oncol., November 20, 2009; 27(33): 5594 - 5600. [Abstract] [Full Text] [PDF]

				M. BREMKE, P.J. BARTH, A.M. SESTERHENN, V. BUDACH, R. ENGENHART-CABILLIC, and J.A. WERNER Prospective Study on Neck Dissection after Primary Chemoradiation Therapy in Stage IV Pharyngeal Cancer Anticancer Res, July 1, 2009; 29(7): 2645 - 2653. [Abstract] [Full Text] [PDF]

				M. Kawashima, H. Fujii, R. Hayashi, M. Tahara, K. Nasu, S. Arahira, and T. Ogino Influence of Delayed Tumor Clearance on Reliability of Complete Response Rate in Chemoradiotherapy for Head and Neck Cancer Jpn. J. Clin. Oncol., August 2, 2007; (2007) hym072v1. [Abstract] [Full Text] [PDF]

				A. Tan, D. J. Adelstein, L. A. Rybicki, J. P. Saxton, R. M. Esclamado, B. G. Wood, R. R. Lorenz, M. Strome, and M. A. Carroll Ability of Positron Emission Tomography to Detect Residual Neck Node Disease in Patients With Head and Neck Squamous Cell Carcinoma After Definitive Chemoradiotherapy Arch Otolaryngol Head Neck Surg, May 1, 2007; 133(5): 435 - 440. [Abstract] [Full Text] [PDF]

				A. S. Tsao, A. S. Garden, M. S. Kies, W. Morrison, L. Feng, J. J. Lee, F. Khuri, R. Zinner, J. Myers, V. Papadimitrakopoulou, et al. Phase I/II Study of Docetaxel, Cisplatin, and Concomitant Boost Radiation for Locally Advanced Squamous Cell Cancer of the Head and Neck J. Clin. Oncol., September 1, 2006; 24(25): 4163 - 4169. [Abstract] [Full Text] [PDF]

				K. S. Chufal, M. Rastogi, M. Srivastava, M. C. Pant, M. L. B. Bhatt, and K. Srivastava Analysis of Prognostic Variables among Patients with Locally Advanced Head and Neck Cancer Treated with Late Chemo-Intensification Protocol: Impact of Nodal Density and Total Tumor Volume Jpn. J. Clin. Oncol., September 1, 2006; 36(9): 537 - 546. [Abstract] [Full Text] [PDF]

				D. Rischin, R. J. Hicks, R. Fisher, D. Binns, J. Corry, S. Porceddu, and L. J. Peters Prognostic Significance of [18F]-Misonidazole Positron Emission Tomography-Detected Tumor Hypoxia in Patients With Advanced Head and Neck Cancer Randomly Assigned to Chemoradiation With or Without Tirapazamine: A Substudy of Trans-Tasman Radiation Oncology Group Study 98.02 J. Clin. Oncol., May 1, 2006; 24(13): 2098 - 2104. [Abstract] [Full Text] [PDF]

				L. W.T. Alkureishi, R. de Bree, and G. L. Ross RADPLAT: An Alternative to Surgery? Oncologist, May 1, 2006; 11(5): 469 - 480. [Abstract] [Full Text] [PDF]

				S. L. Liauw, A. A. Mancuso, R. J. Amdur, C. G. Morris, D. B. Villaret, J. W. Werning, and W. M. Mendenhall Postradiotherapy Neck Dissection for Lymph Node-Positive Head and Neck Cancer: The Use of Computed Tomography to Manage the Neck J. Clin. Oncol., March 20, 2006; 24(9): 1421 - 1427. [Abstract] [Full Text] [PDF]

				D. Rischin, L. Peters, R. Fisher, A. Macann, J. Denham, M. Poulsen, M. Jackson, L. Kenny, M. Penniment, J. Corry, et al. Tirapazamine, Cisplatin, and Radiation Versus Fluorouracil, Cisplatin, and Radiation in Patients With Locally Advanced Head and Neck Cancer: A Randomized Phase II Trial of the Trans-Tasman Radiation Oncology Group (TROG 98.02) J. Clin. Oncol., January 1, 2005; 23(1): 79 - 87. [Abstract] [Full Text] [PDF]

				A.S. Garden, J. Harris, E.E. Vokes, A.A. Forastiere, J.A. Ridge, C. Jones, E.M. Horwitz, B.S. Glisson, L. Nabell, J.S. Cooper, et al. Preliminary Results of Radiation Therapy Oncology Group 97-03: A Randomized Phase II Trial of Concurrent Radiation and Chemotherapy for Advanced Squamous Cell Carcinomas of the Head and Neck J. Clin. Oncol., July 15, 2004; 22(14): 2856 - 2864. [Abstract] [Full Text] [PDF]

				W. F. Regine, J. Valentino, S. M. Arnold, R. C. Haydon, D. Sloan, D. Kenady, J. Strottmann, C. Pulmano, and M. Mohiuddin High-Dose Intra-Arterial Cisplatin Boost With Hyperfractionated Radiation Therapy for Advanced Squamous Cell Carcinoma of the Head and Neck J. Clin. Oncol., July 15, 2001; 19(14): 3333 - 3339. [Abstract] [Full Text] [PDF]

				D. Rischin, L. Peters, R. Hicks, P. Hughes, R. Fisher, R. Hart, M. Sexton, I. D'Costa, and R. von Roemeling Phase I Trial of Concurrent Tirapazamine, Cisplatin, and Radiotherapy in Patients With Advanced Head and Neck Cancer J. Clin. Oncol., January 15, 2001; 19(2): 535 - 542. [Abstract] [Full Text] [PDF]